Suciraslimab, identified by the CAS number 2415439-63-1, is a monoclonal antibody designed for therapeutic applications, particularly in the treatment of autoimmune diseases. As a biologic, it is characterized by its specificity to target certain proteins or cells in the immune system, thereby modulating immune responses. Monoclonal antibodies like Suciraslimab are typically produced using recombinant DNA technology, which allows for the generation of highly specific and consistent therapeutic agents. The mechanism of action often involves binding to specific antigens, leading to the inhibition of inflammatory pathways or the enhancement of immune regulation. Suciraslimab's pharmacokinetics, including its absorption, distribution, metabolism, and excretion, are influenced by its molecular structure and the presence of glycosylation patterns, which can affect its stability and efficacy. As with many biologics, potential side effects may include infusion reactions or increased susceptibility to infections, necessitating careful monitoring during treatment. Overall, Suciraslimab represents a targeted approach in the evolving landscape of immunotherapy.

Suciraslimab

2415439-63-1: Suciraslimab, identified by the CAS number 2415439-63-1, is a monoclonal antibody designed for therapeutic applications, particularly in the treatment of autoimmune diseases. As a biologic, it is characterized by its specificity to target certain proteins or cells in the immune system, thereby modulating immune responses. Monoclonal antibodies like Suciraslimab are typically produced using recombinant DNA technology, which allows for the generation of highly specific and consistent therapeutic agents. The mechanism of action often involves binding to specific antigens, leading to the inhibition of inflammatory pathways or the enhancement of immune regulation. Suciraslimab's pharmacokinetics, including its absorption, distribution, metabolism, and excretion, are influenced by its molecular structure and the presence of glycosylation patterns, which can affect its stability and efficacy. As with many biologics, potential side effects may include infusion reactions or increased susceptibility to infections, necessitating careful monitoring during treatment. Overall, Suciraslimab represents a targeted approach in the evolving landscape of immunotherapy.

<p>Suciraslimab (SM03) is a human IgG1 monoclonal antibody against the B-cell restriction antigen CD22 for rheumatoid arthritis (RA) and B-cell related diseases.</p>

CAS 2415439-63-1

Suciraslimab

Suciraslimab

Ref: TM-T9901A-522